The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients - Wikidata - awgldk - TriplyDB

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

http://www.wikidata.org/entity/Q34086952

about

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives Individualising treatment choices in a crowded treatment algorithm Medical treatment of renal cancer: new horizons Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment.Experience with sunitinib in the treatment of metastatic renal cell carcinoma Nivolumab in renal cell carcinoma: latest evidence and clinical potential.Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors.Current management and future perspectives of metastatic renal cell carcinoma.Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe.Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line.Prognostic Significance of Early Tumor Shrinkage Under Second-Line Targeted Therapy for Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Study in Japan.Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry.Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.Evaluation of tumor burden after sequential molecular-targeted therapy in patients with metastatic renal cell carcinoma.Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis.

P2860

Q26751341-0712F322-0D55-46F6-AE5B-F0276D30C021 Q27023669-B1A6C94D-6BF9-4CBA-8562-FE7DB865279E Q28073174-93A983B5-7402-47B9-A1A0-77358AD57716 Q33750154-22AC6C77-C4BE-44BA-8A38-8464CD13CCC5 Q36067852-29802175-F646-4690-A3D8-A15504353D50 Q36231729-D9DAD260-7719-4043-A271-28AAF343AD82 Q37698611-993DC68E-CF79-4EE6-A59A-6D20D35BB937 Q38116001-90A3E8F5-6BA7-484B-B0EE-ED8C006E4804 Q38214976-23E83EAA-7A61-4FAA-AD46-68609DF444B2 Q38653213-9ABE6ED8-B5D0-4EE8-A498-1A9F632BBFDD Q38656760-1D9FB16A-4F99-4EC5-8883-AF1306579DB8 Q40754987-8C6F3791-67A7-481F-B562-03E911099795 Q41735562-B30EB5CB-CE9C-4516-8A56-3DE158E5E970 Q47265255-68DC2187-7170-4442-9C88-996C4364A1D6 Q50049497-8DD8E01B-7C9B-4FC7-8281-32862F58B5BB Q50984279-E8D14891-3A3B-4FB6-BA11-D283C52D418F Q53062408-EDA7A0AE-9F02-4100-B19F-4BB3156D489A Q53634559-D51F24C1-63EB-40A3-ACFC-AC29F4203FE9

P2860

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

http://www.wikidata.org/entity/Q34086952

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

The association of clinical ou ...... renal cell carcinoma patients

@ast

The association of clinical ou ...... renal cell carcinoma patients

@en

The association of clinical ou ...... renal cell carcinoma patients

@nl

type

label

The association of clinical ou ...... renal cell carcinoma patients

@ast

The association of clinical ou ...... renal cell carcinoma patients

@en

The association of clinical ou ...... renal cell carcinoma patients

@nl

prefLabel

The association of clinical ou ...... renal cell carcinoma patients

@ast

The association of clinical ou ...... renal cell carcinoma patients

@en

The association of clinical ou ...... renal cell carcinoma patients

@nl

P1433

Q34086952-B8498A71-1779-4EB6-89C0-AC687440008A

P1476

Q34086952-B39EB24B-6508-4D42-BB03-8DE07319AE1F

P2093

Q34086952-06AD59F0-0C10-4A8D-BCFA-A27B08B27BA6

Q34086952-0EB382DC-A6D2-4AC5-8742-050C59ADAD32

Q34086952-24BB0E0F-166D-48A1-9B3B-B5E677FF14CD

Q34086952-3412A54D-2091-495E-9DCF-0BF4D1499DE1

Q34086952-3E6E570D-5DED-4264-86FC-DEAC0DD99BCA

Q34086952-467F057B-3DF4-47E4-A1D6-AF8B9221906B

Q34086952-5E4B501D-78EC-4BC1-8B86-7CE86CEBB8B7

Q34086952-5E4F20C2-9B5E-4781-9BB5-EB64379424EC

Q34086952-5F019F7C-4F52-446E-BD13-34BD862A87A8

Q34086952-63A19E7F-6AC3-4851-A2B7-BBCBAA9B231D

P2860

Q34086952-02C85E69-5A70-47AC-BED9-F194A1A218BB

Q34086952-0D1D293B-DB1E-4E83-ACBA-9633419554C8

Q34086952-109EB5D9-801C-4992-95F3-4E5FD5A207FE

Q34086952-171CB5B8-3388-452A-88F9-CBBE6325023C

Q34086952-2045FBEF-2151-41E8-9B2A-08B89F027939

Q34086952-27943A93-2F8F-47E7-9A43-0C65A006BA02

Q34086952-3049412E-149A-4E49-813C-C3589E664B77

Q34086952-42459BA4-8D7A-452D-9AF1-51F6C5256AF8

Q34086952-58ED23CE-4039-42F3-9D37-8E67CC3701DB

Q34086952-7D05F706-6429-47F6-8F6A-D99B86B56FCA

P2888

Q34086952-3A5A313B-AD9F-476B-9785-35E171CA72DD

P304

Q34086952-75F10847-085F-4961-8928-628660A0F9C6

P31

Q34086952-EE45AFE6-7337-441B-BC24-31A1F43F5D0A

P356

Q34086952-AE007EF3-62D4-4218-9C0D-982C76A9FE1A

P433

Q34086952-F94F55EB-158E-4A89-B2A1-F08BD1DA81FC

P478

Q34086952-624ABFEE-4D60-486A-8047-292F37310085

P577

Q34086952-F0F20D8F-0083-4757-89A5-F5EA5BB2D420

P5875

Q34086952-2798C658-58C3-4013-BB8B-93FF6E8A8FD4

P6179

Q34086952-B63D82BF-39AE-4A48-B399-51D58446BD77

P698

Q34086952-FCC22BE1-CFFB-4C2A-8B32-51C9BC4D877E

P932

Q34086952-25B1A917-91A4-4991-9E51-AC98BC99FEB1

P356

S11523-012-0252-7

P1433

Targeted oncology

P1476

The association of clinical ou ...... renal cell carcinoma patients

@en

P2093

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Christian Kollmannsberger

http://www.w3.org/2001/XMLSchema#string

Daniel Y Heng

http://www.w3.org/2001/XMLSchema#string

Frede N Donskov

http://www.w3.org/2001/XMLSchema#string

Georg Bjarnason

http://www.w3.org/2001/XMLSchema#string

Hulayel Al-Harbi

http://www.w3.org/2001/XMLSchema#string

International mRCC Database Consortium

http://www.w3.org/2001/XMLSchema#string

Jennifer J Knox

http://www.w3.org/2001/XMLSchema#string

Lauren C Harshman

http://www.w3.org/2001/XMLSchema#string

Lori Wood

http://www.w3.org/2001/XMLSchema#string

P2860

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

P2888

s11523-012-0252-7

P304

203-209

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-012-0252-7

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234089649

http://www.w3.org/2001/XMLSchema#string

P6179

1012774118

http://www.w3.org/2001/XMLSchema#string

P698

23300029

http://www.w3.org/2001/XMLSchema#string

P932

4144038

http://www.w3.org/2001/XMLSchema#string